Species differences in histomorphometry

Similar documents
Assessment and Treatment of Osteoporosis Professor T.Masud

HRT and Risedronate Combined Anabolic and Antiresorptive Therapy

Bone Cell Biology. David W. Dempster, PhD. Professor of Clinical Pathology Columbia University. Bone Remodeling

Bone Cell Biology. The Remodeling Cycle. Bone Remodeling. Remodeling Maintains Mechanical Strength. David W. Dempster, PhD

OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010

7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

Osteoclast Culture Kit

Siglec-15 Is A Potential Therapeutic Target For Postmenopausal Osteoporosis

Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis

New Agents for Myeloma Bone Disease

How cancellous and cortical bones adapt to loading and growth hormone

Fig. S1 A. week 4 week 6

Nature Medicine: doi: /nm.4324

SpongeBone Menopants*

NEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN

Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD

Presenter: 翁家嫻 Venue date:

Disclosures CONSULTANT WRIGHT MEDICAL CONSULTANT ORTHO FIX

Osteoporosis Update. Greg Summers Consultant Rheumatologist

PART FOUR. Metabolism and Nutrition

TEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine

Modélisation par éléments finis des effets des médicaments sur le remodelage osseux : Approche mécanobiologique

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Monitoring Osteoporosis Therapy

Upcoming Agents for Osteoporosis

Icd 10 code metastatic bone disease

THE GROWING GAP IN OSTEOPOROSIS TREATMENT

Hierarchical Microimaging of Bone Structure and Function

An Update on Osteoporosis Treatments

ANATOMY C027A: MINERALIZED TISSUE BIOLOGY: SKELETAL TISSUES. Please answer THREE Questions. All questions carry equal marks.

Opg/Rankl mrna dynamic expression in the bone tissue of ovariectomized rats with osteoporosis

Rama Nada. - Mousa Al-Abbadi. 1 P a g e

Osteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark

Supplemental figures and figure legends (90517-INS-RG-RV-2) Supplemental Figure 1.

TITLE: Effect of a High Bone Turnover State Induced by Estrogen Deficiency on the Development and Progression of Breast Cancer Bone Metastases

BONE HISTOLOGY SLIDE PRESENTATION

Osteoclast Culture Kit

New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism

Estrogen receptor α- (ERα), but not ERβ-signaling, is crucially involved in mechanostimulation of bone fracture healing by whole-body vibration

Drugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics

Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis

A KL/R / AN A K/O / P O G G

A Novel Murine Model Of Adynamic Bone Disease (ABD)

Osteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic

Supplementary Material for

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page

Figure 1. Dnmt3b expression in murine and human knee joint cartilage. (A) Representative images

BONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology

Osteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus

What is Osteoporosis?

Introduction to Biomedical Engineering: Basic concepts and Bone Biomechanics

Bone and Cancer. Peter Croucher

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

The purpose of this practical session is to demonstrate cartilage and bone as specialized connective tissues to the student.

Current and Emerging Strategies for Osteoporosis

Lecture 3: Skeletogenesis and diseases

Comment les cellules osseuses communiquent entre elles. Gérard Friedlander Journées UPA 2011

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Bone mechanics bone strength and beyond

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Mutation in Osteoactivin Enhances RANKL-Mediated Signaling, Promoting Osteoclast Differentiation, Survival and Inhibiting Bone Resorption

The Pathogenesis of Bone Erosions in RA FULL VERSION

Review Article Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis

Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis

The Skeletal System. Chapter 7a. Skeletal System Introduction Functions of the skeleton Framework of bones The skeleton through life

DISCLOSURES TOPICS" PATHOPHYSIOLOGY of OSTEOPOROSIS: Pathways That Control Bone Remodeling! Why Do Bones Remodel?" Nothing to disclose

Regulation of the skeletal mass through the life span

BONE TISSUE. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology

Supplementary data Supplementary Figure 1 Supplementary Figure 2

Bio 103 Skeletal System 45

Mouse Glu-OC (undercarboxylated osteocalcin) and Gla-OC (carboxylated osteocalcin) levels were

Differentiating Pharmacological Therapies for Osteoporosis

SUPPLEMENTARY INFORMATION

Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis

Skeletal Tissues. Skeletal tissues. Frame; muscles, organs and CT attach. Brain, spinal cord, thoracic organs; heart and lungs.

DENOSUMAB (PROLIA & XGEVA )

Download slides:

Osteoporosis. Treatment of a Silently Developing Disease

Interactions between bone and the central nervous system Florent Elefteriou, PhD

New treatments of osteoporosis

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

Imaging to Assess Bone Strength and its Determinants

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

BIOLOGY and BIOMECHANICS OF NORMAL & OSTEOPOROTIC BONE

Osteocyte Wnt/ -Catenin Signaling Is Required for Normal Bone Homeostasis

Effects of Whole Body Exposure to Electromagnetic Field on Normal and Osteoporotic Bone Metabolism in Rats

As the most common bone disease in

The Skeletal System. Chapter 4

TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Collagen Crosslinks, Any Method

Osteoclasts- What Do They Do and How Do They Do It? Prof. Steven L. Teitelbaum

Collagen Crosslinks, Any Method

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

Transcription:

Species differences in histomorphometry Reinhold G. Erben Department of Biomedical Sciences Institute of Physiology and Pathophysiology University of Veterinary Medicine Vienna

Purpose of histomorphometry Histomorphometry is always related to mechanistic questions or safety issues Bone structure Bone formation Bone resorption Bone mineralization Bone modeling and remodeling

Important issues Strain-, gender-, age-related and site specific differences in bone structure and bone mass Differences in osteoclast morphology Differences in osteoblast morphology and assessment of bone formation Differences in cancellous and cortical bone remodeling Differences in the physiologic response to bone-active drugs

Gender-related differences in mice Female Female Male Male Estrogen is a bone anabolic hormone in mice, unlike other mammalian species. Schmidt et al. Am J Pathol 155:557, 1999

Age-related changes in mice 3 mo 3 mo 1 y

Age-related changes in rats 4 mo 2 2 y yorx

Vertebrae in mice and rats 3 mo 10 mo 22-mo-old rats SHAM ORX

Example: Efficacy of denosumab in GIO model Murine RANKL genomic structure Exon 1 2 3 4 5 3 non-coding region RANKL targeting vector Human Ex 5 Neo Short arm Long arm LoxP LoxP TK TK Mu 3 non-coding region hurankl Knock-in allele Human Ex 5 Neo LoxP LoxP Exon 1 2 3 4 5 Mu 3 non-coding region (Kostenuik et al., JBMR 24:182, 2009)

OPG/RANKL system RANK: Receptor activator of NFκB OPG: Osteoprotegerin RANKL: RANK ligand Stromal cell/t cell Oc precursor srankl RANK Denosumab Osteoclast Differentiation Fusion RANKL Denosumab OPG Osteoblasts/Stromal cells

Example: Efficacy of denosumab in GIO model 0.3 Bone formation rate L1 125 Serum osteocalcin (µm²/µm/day) 0.2 0.1 (ng/ml) 100 75 50 25 0.0 C Pred WT PBS Ab Control PBS Pred hrankl KI Ab Two-way ANOVA Effect of Pred: NS Effect of Denosumab: p<0.001 0 C WT Pred PBS Ab Control PBS Pred hrankl KI Ab Two-way ANOVA Effect of Pred: NS Effect of Denosumab: p=0.012 Hofbauer et al. Arthritis Rheum 60:1427, 2009

Example: Efficacy of denosumab in GIO model Bone formation rate distal femur (µm²/µm/day) 0.5 0.4 0.3 0.2 0.1 0.0 PBS Ab PBS Ab C Pred Control WT Pred hrankl KI Two-way ANOVA Effect of Pred: NS Effect of Denosumab: p<0.001 In aged mice or severely osteopenic rats, always take out the verts! Hofbauer et al. Arthritis Rheum 60:1427, 2009

Differences in osteoclast morphology

Differences in osteoclast morphology Reliable detection of osteoclasts in mice should be based on TRAPstained sections! Therefore, it is necessary to use a methylmethacrylate mixture suitable for histochemistry (e.g., Erben, J Histochem Cytochem 45:307,1997), or to decalcify bone specimens.

Differences in osteoblast morphology Marker interval (cancellous bone formation!) 1 day in 3 4-wk-old mice 2 days in 8 12-wk-old mice 2-3 days in aged mice >5 mo 4-5 days in rats

Do mice and rats have bone remodeling? Rabbit Rat Mouse Gefäßkanal

Do rats and mice have bone remodeling?

Age dependent changes in modeling and remodeling Proximal tibial cancellous bone % of all formation sites 75 50 25 0 3 months 6 months 9 months 12 months Age %Remodeling %Modeling %Uncertain (Erben 1996) Erben Anat Rec 246:39, 1996

Age dependent changes in modeling and remodeling Lumbar vertebral cancellous bone % of all formation sites 100 75 50 25 0 3 months 6 months 12 months Age %Remodeling %Modeling %Uncertain (Erben, 1996) Erben Anat Rec 246:39, 1996

Age dependent changes in modeling and remodeling Longitudinal bone growth in the proximal tibia and L1 of female Fischer rats µm/day 40 30 20 Proximal tibia L1, cranial growth plate L1, caudal growth plate 10 0 3 months 6 months 9 months 12 months Age Erben Anat Rec 246:39, 1996

Labeling escape error MI1 MI2 To minimize the labeling escape error, the marker interval should be less than about 1/5 of the formation period. Time MI3 More information: Erben RG (2003) Bone Labeling Techniques. In: Handbook of Histology Methods for Bone and Cartilage. An YH, Martin KL (eds) Humana Press Inc., Totowa, NJ, USA, pp 99 117

Bone remodeling in rats and mice Rat vertebral cancellous bone 120 100 80 FP RsP RmP (days) 60 40 20 0 3 months 6 months 9 months 12 months Age

Bone remodeling in rats and mice Murine vertebral cancellous bone 40 30 FP RsP RmP (days) 20 10 0 3 months 6 months 9 months 12 months Age

Differences in physiological response to drugs (mg/cm³) 500 475 450 425 400 375 350 300 0 Total BMD L4 * P<0.05 vs. Veh * Veh PTH Veh PTH Male Female Gender-related skeletal effect of cyclosporin A (ng/ml) Erben et al. Endocrinology 144:40, 2003 600 400 200 0 CsA blood concentration 800 Males Females SHAM GX GX+HRT Female rats have a 7-fold higher hepatic CsA excretion rate relative to males in steady state.

Betacellulin transgenic mice Male Female 3 wk 6 wk 9 wk 3 wk 6 wk 9 wk wt tg Schneider et al. JBMR 24:455, 2009

Take home messages Always take out vertebrae in aged mice and severely osteopenic rats. For the quantification of osteoclasts in mice always use TRAP staining. For the assessment of bone formation fluorochrome labeling with an appropriate marker interval is essential. Rats and mice lack true Haversian cortical bone remodeling, but not cancellous bone remodeling activity. Consider species specific effects of certain drugs in rats and mice (e.g., CsA in rats, estrogen and PTH in mice).

Acknowledgements Institute of Physiology & Pathophysiology University of Veterinary Medicine Vienna Ute Zeitz Claudia Bergow Christiane Schüler Kerstin Klien Institute of Animal Physiology LMU Munich Karin Begsteiger Sieglinde Hirmer Technical University Dresden Lorenz Hofbauer Gene Center LMU Munich Marlon Schneider Eckhard Wolf

ISBM Meeting, Zell am See, Austria, May 28 30, 2009 Special feature: One-day hands-on practical training course on May 28 www.bonemorphometry.org